Brief: Roche Receives CE Mark For First IVD Immunoassay Blood Test To Identify Carriers Of ApoE4
16/03/2026 06:04
March 16 (Reuters) - ROCHE HOLDING AG ROG.S: RECEIVES CE MARK FOR FIRST IVD IMMUNOASSAY BLOOD TEST TO IDENTIFY CARRIERS OF APOE4, A GENETIC VARIANT PRESENT IN UP TO 60% OF PATIENTS DIAGNOSED WITH ALZHEIMER'S DISEASE Source text: ID:nPn8YMnFa Further company coverage: ROG.S (Gdansk Newsroom) ((((gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza